<DOC>
	<DOC>NCT00273299</DOC>
	<brief_summary>The purpose of this study is to assess the potential of using valsartan/HCTZ as initial therapy in patients with severe hypertension compared to valsartan alone as initial therapy, and to determine whether a greater proportion of patients achieve blood pressure control with the combination compared to the monotherapy without producing an unacceptable adverse event profile.</brief_summary>
	<brief_title>Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Diagnosed severe hypertension Inability to discontinue all prior antihypertensive medications Heart failure of any kind History of stroke, transient ischemic attack, myocardial infarction, chest pain, abnormal heart rhythm Liver, kidney, or pancreas disease Diabetes with poor glucose control Allergy to certain medications used to treat high blood pressure Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>hypertension</keyword>
	<keyword>high blood pressure</keyword>
	<keyword>valsartan/hydrochlorozide</keyword>
	<keyword>severe hypertension</keyword>
</DOC>